<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113241</url>
  </required_header>
  <id_info>
    <org_study_id>DAPA-MS</org_study_id>
    <nct_id>NCT02113241</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion</brief_title>
  <official_title>Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult
      population suffers the disease.

      Dapagliflozin is an inhibitor of the sodium-glucose co-transporter SGLT2 in the kidney and is
      a novel treatment for diabetes type 2. Some studies indicate that SGLT2 inhibitors have
      benefits on blood pressure, triglycerides levels and help to raise the levels of high density
      lipoproteins cholesterol (c-HDL).

      The aim of this study is to evaluate the effect of dapagliflozin on metabolic syndrome,
      insulin sensitivity and insulin secretion.

      The investigators hypothesis is that the administration of dapagliflozin modifies the
      metabolic syndrome, insulin sensitivity and insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial its going to carry out in 24
      patients with a diagnosis of metabolic syndrome in accordance with the International Diabetes
      Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and
      acid uric are going to be load after a 75 g of dextrose load.

      12 patients will receive Forxiga (dapagliflozin), 10 mg, one per day before breakfast during
      3 months.

      The remaining 12 patients will receive placebo at the same dose.

      There will be calculated Area Under the Curve of glucose and insulin, total insulin secretion
      (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
      sensitivity (Matsuda index).

      This protocol it's already approved by the local ethics committee and written informed
      consent it's going to be obtained from all volunteers.

      Results will be presented as mean and standard deviation. Intra and inter group differences
      are going to be tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively;
      p≤0.05 it's going to be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of waist circumference at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The waist circumference is going to be evaluated at baseline and week 12 with a flexible tape with standardized techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of triglycerides levels at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The triglycerides levels are going to be evaluated at baseline and week 12 with enzymatic-colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of high density lipoprotein (c-HDL) levels at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The c-HDL levels are going to be evaluated at baseline and week 12 with enzymatic/colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of fasting glucose levels at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The fasting glucose levels are going to be evaluated at baseline and week 12 with enzymatic/colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of blood pressure at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The blood pressure is going to be evaluated at baseline and week 12 with a digital sphygmomanometer. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of first phase of insulin secretion at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The first phase of insulin secretion is going to be calculated at baseline and week 12 with Stumvoll index. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of total insulin secretion at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The total insulin secretion is going to be calculated at baseline and week 12 with insulinogenic index. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of total insulin sensitivity at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The insulin sensitivity is going to be calculated at baseline and week 12 with Matsuda index. Differences will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of weight at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The weight it's going to be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance. Differences will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Body Mass Index at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The Body Mass index it's going to be calculated at baseline and at week 12 with the Quetelet index. Differences will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total cholesterol at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The total cholesterol will be estimated by standardized techniques at baseline and week 12. Differences will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of low density lipoproteins (c-LDL) at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The c-LDL levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hepatic transaminases at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <description>The hepatic transaminases levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of creatinine at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <description>The creatinine levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of uric acid at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <description>The uric acid levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients both sexes

          -  Age between 30 and 60 years

          -  Metabolic Syndrome according to the IDF criteria

          -  Waist circumference

          -  Man ≥90 cm

          -  Woman ≥80 cm

          -  And two of the following criteria

          -  High density lipoprotein

          -  Man ≤40 mg/dL

          -  Woman ≤50 mg/dL

          -  Fasting glucose ≥100 mg/dL

          -  Triglycerides ≥150 mg/dL

          -  Blood pressure ≥130/85 mmHg

          -  Informed consent signed

        Exclusion Criteria:

          -  Women with confirmed or suspected pregnancy

          -  Women under lactation and/or puerperium

          -  Hypersensibility to SGLT2 inhibitors

          -  Physical impossibility for taking pills

          -  Known uncontrolled renal, hepatic, heart or thyroid diseased

          -  Previous treatment for the metabolic syndrome components

          -  Body Mass Index ≥39.9 kg/m2

          -  Fasting glucose ≥126 mg/dL

          -  Triglycerides ≥500 mg/dL

          -  Total cholesterol ≥240 mg/dL

          -  Low density lipoprotein (c-LDL) ≥190 mg/dL

          -  Blood Pressure ≥140/90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.</citation>
    <PMID>22238392</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.</citation>
    <PMID>22446170</PMID>
  </results_reference>
  <results_reference>
    <citation>Chao EC. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid. 2012;7:21-8. doi: 10.2147/CE.S16359. Epub 2012 Jun 1.</citation>
    <PMID>22701099</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.</citation>
    <PMID>24105299</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013 Aug;35(8):1211-1222.e2. doi: 10.1016/j.clinthera.2013.06.017. Epub 2013 Aug 2.</citation>
    <PMID>23910664</PMID>
  </results_reference>
  <results_reference>
    <citation>Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8.</citation>
    <PMID>19996149</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.</citation>
    <PMID>23210765</PMID>
  </results_reference>
  <results_reference>
    <citation>Kilov G, Leow S, Thomas M. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes. Aust Fam Physician. 2013 Oct;42(10):706-10. Review.</citation>
    <PMID>24130972</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25.</citation>
    <PMID>23194084</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010 Jun;12(6):510-6. doi: 10.1111/j.1463-1326.2010.01216.x.</citation>
    <PMID>20518806</PMID>
  </results_reference>
  <results_reference>
    <citation>Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.</citation>
    <PMID>23668478</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.</citation>
    <PMID>20566676</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29.</citation>
    <PMID>23906445</PMID>
  </results_reference>
  <results_reference>
    <citation>Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 May 1;124(5):2287.</citation>
    <PMID>24463448</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>forxiga</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

